Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study
•Low dose of LSD (5 and 20 mcg) enhances sustained attention.•Low dose of LSD (20 mcg) reduces speed of information processing.•Low dose of LSD affects mood states in positive directions (5, 10 and 20 mcg).•Low dose of LSD increased anxiety (5 and 20 mcg) and confusion (20 mcg).•Most apparent affect...
Saved in:
Published in | European neuropsychopharmacology Vol. 41; pp. 81 - 91 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.12.2020
|
Subjects | |
Online Access | Get full text |
ISSN | 0924-977X 1873-7862 1873-7862 |
DOI | 10.1016/j.euroneuro.2020.10.002 |
Cover
Abstract | •Low dose of LSD (5 and 20 mcg) enhances sustained attention.•Low dose of LSD (20 mcg) reduces speed of information processing.•Low dose of LSD affects mood states in positive directions (5, 10 and 20 mcg).•Low dose of LSD increased anxiety (5 and 20 mcg) and confusion (20 mcg).•Most apparent affects are present following 20 mcg of LSD.
There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to affect mood and cognition. A placebo-controlled within-subject study including 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience, up until 6 h after administration. Cognition and subjective experience were assessed using the Psychomotor Vigilance Task, Digit Symbol Substitution Test, Cognitive Control Task, Profile of Mood States, and 5-Dimensional Altered States of Consciousness rating scale. LSD showed positive effects in the majority of observations by increasing positive mood (20 mcg), friendliness (5, 20 mcg), arousal (5 mcg), and decreasing attentional lapses (5, 20 mcg). Negative effects manifested as an increase in confusion (20 mcg) and anxiety (5, 20 mcg). Psychedelic-induced changes in waking consciousness were also present (10, 20 mcg). Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations. The minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg. |
---|---|
AbstractList | There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to affect mood and cognition. A placebo-controlled within-subject study including 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience, up until 6 h after administration. Cognition and subjective experience were assessed using the Psychomotor Vigilance Task, Digit Symbol Substitution Test, Cognitive Control Task, Profile of Mood States, and 5-Dimensional Altered States of Consciousness rating scale. LSD showed positive effects in the majority of observations by increasing positive mood (20 mcg), friendliness (5, 20 mcg), arousal (5 mcg), and decreasing attentional lapses (5, 20 mcg). Negative effects manifested as an increase in confusion (20 mcg) and anxiety (5, 20 mcg). Psychedelic-induced changes in waking consciousness were also present (10, 20 mcg). Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations. The minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg. •Low dose of LSD (5 and 20 mcg) enhances sustained attention.•Low dose of LSD (20 mcg) reduces speed of information processing.•Low dose of LSD affects mood states in positive directions (5, 10 and 20 mcg).•Low dose of LSD increased anxiety (5 and 20 mcg) and confusion (20 mcg).•Most apparent affects are present following 20 mcg of LSD. There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to affect mood and cognition. A placebo-controlled within-subject study including 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience, up until 6 h after administration. Cognition and subjective experience were assessed using the Psychomotor Vigilance Task, Digit Symbol Substitution Test, Cognitive Control Task, Profile of Mood States, and 5-Dimensional Altered States of Consciousness rating scale. LSD showed positive effects in the majority of observations by increasing positive mood (20 mcg), friendliness (5, 20 mcg), arousal (5 mcg), and decreasing attentional lapses (5, 20 mcg). Negative effects manifested as an increase in confusion (20 mcg) and anxiety (5, 20 mcg). Psychedelic-induced changes in waking consciousness were also present (10, 20 mcg). Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations. The minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg. There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to affect mood and cognition. A placebo-controlled within-subject study including 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience, up until 6 h after administration. Cognition and subjective experience were assessed using the Psychomotor Vigilance Task, Digit Symbol Substitution Test, Cognitive Control Task, Profile of Mood States, and 5-Dimensional Altered States of Consciousness rating scale. LSD showed positive effects in the majority of observations by increasing positive mood (20 mcg), friendliness (5, 20 mcg), arousal (5 mcg), and decreasing attentional lapses (5, 20 mcg). Negative effects manifested as an increase in confusion (20 mcg) and anxiety (5, 20 mcg). Psychedelic-induced changes in waking consciousness were also present (10, 20 mcg). Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations. The minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg.There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to affect mood and cognition. A placebo-controlled within-subject study including 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience, up until 6 h after administration. Cognition and subjective experience were assessed using the Psychomotor Vigilance Task, Digit Symbol Substitution Test, Cognitive Control Task, Profile of Mood States, and 5-Dimensional Altered States of Consciousness rating scale. LSD showed positive effects in the majority of observations by increasing positive mood (20 mcg), friendliness (5, 20 mcg), arousal (5 mcg), and decreasing attentional lapses (5, 20 mcg). Negative effects manifested as an increase in confusion (20 mcg) and anxiety (5, 20 mcg). Psychedelic-induced changes in waking consciousness were also present (10, 20 mcg). Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations. The minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg. |
Author | Mason, Natasha L. Dolder, Patrick C. Kuypers, Kim P.C. Hutten, Nadia R.P.W. Feilding, Amanda Theunissen, Eef L. Liechti, Matthias E. Ramaekers, Johannes G. Holze, Friederike |
Author_xml | – sequence: 1 givenname: Nadia R.P.W. surname: Hutten fullname: Hutten, Nadia R.P.W. organization: Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht, the Netherlands – sequence: 2 givenname: Natasha L. surname: Mason fullname: Mason, Natasha L. organization: Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht, the Netherlands – sequence: 3 givenname: Patrick C. surname: Dolder fullname: Dolder, Patrick C. organization: Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht, the Netherlands – sequence: 4 givenname: Eef L. surname: Theunissen fullname: Theunissen, Eef L. organization: Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht, the Netherlands – sequence: 5 givenname: Friederike surname: Holze fullname: Holze, Friederike organization: Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland – sequence: 6 givenname: Matthias E. surname: Liechti fullname: Liechti, Matthias E. organization: Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland – sequence: 7 givenname: Amanda surname: Feilding fullname: Feilding, Amanda organization: The Beckley Foundation, Beckley Park, Oxford, UK – sequence: 8 givenname: Johannes G. surname: Ramaekers fullname: Ramaekers, Johannes G. organization: Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht, the Netherlands – sequence: 9 givenname: Kim P.C. surname: Kuypers fullname: Kuypers, Kim P.C. organization: Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht, the Netherlands |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33082016$$D View this record in MEDLINE/PubMed |
BookMark | eNqNks9vFCEcxYmpsdvqv6AcvcwWhmF-mBizqVpN1nhQE2-EhS8tKwtbYNrMxb9ddrf20NNeIHm894APnKETHzwg9IaSOSW0vVjPYYxFKsO8JvVOnRNSP0Mz2nes6vq2PkEzMtRNNXTd71N0ltKaEMoZG16gU8ZIX5eeGfr7LQSNpddYhWtvsw0eS5MhYqk31tuUo9yLwWAX7vHyx0esQ4KErcc3IF2-mfBdcKPPADG9wwu8dVLBKpRCn2NwDvQ-UYExoDI21mvrr3HKo55eoudGugSvHuZz9Ovzp5-XX6rl96uvl4tlpZquzZWUnFHdsU73ph863tBh1fCWcC4Jg6bVPZWEGsoGYLwzmshWEYDeGAqc64ado_7QO_qtnO6lc2Ib7UbGSVAidkjFWjwiFTuku4WCtETfHqLbGG5HSFlsbFLgnPQQxiTqhteF8UD6Yn39YB1XG9CPW_zHXQzvDwYVQ0oRjFA27_kWzNYdcZbuSf74WywOSSiU7yxEkZQFr0DbWF5F6GCP6PjwpEO58kWUdH9gOqrhH4y828U |
CitedBy_id | crossref_primary_10_1038_s41398_024_02900_4 crossref_primary_10_1089_psymed_2024_0005 crossref_primary_10_1177_02698811231225609 crossref_primary_10_1007_s40263_023_01008_5 crossref_primary_10_1016_j_psychres_2024_115886 crossref_primary_10_1177_20494637221114962 crossref_primary_10_2139_ssrn_3910688 crossref_primary_10_7554_eLife_66920 crossref_primary_10_1080_02791072_2022_2080616 crossref_primary_10_1177_02698811211050556 crossref_primary_10_1038_s41380_024_02743_x crossref_primary_10_15406_jpcpy_2023_14_00738 crossref_primary_10_1016_j_evopsy_2021_03_013 crossref_primary_10_3389_fpsyt_2023_1088896 crossref_primary_10_3390_ijms24021329 crossref_primary_10_1111_adb_13143 crossref_primary_10_1007_s00213_022_06106_8 crossref_primary_10_1016_j_neuropharm_2025_110334 crossref_primary_10_1124_pharmrev_120_000056 crossref_primary_10_1080_02791072_2024_2304554 crossref_primary_10_1177_02698811231190865 crossref_primary_10_1016_j_jns_2022_120332 crossref_primary_10_1016_j_bpsc_2024_01_002 crossref_primary_10_1017_S0033291722002963 crossref_primary_10_1007_s00213_021_05991_9 crossref_primary_10_1038_s41598_023_34938_7 crossref_primary_10_1016_j_socscimed_2024_116702 crossref_primary_10_1111_soc4_12959 crossref_primary_10_1186_s40345_022_00265_5 crossref_primary_10_1016_j_nsa_2022_101012 crossref_primary_10_7554_eLife_62878 crossref_primary_10_1176_appi_ajp_20230890 crossref_primary_10_1371_journal_pone_0307491 crossref_primary_10_1186_s13063_021_05243_3 crossref_primary_10_1177_13634615221129115 crossref_primary_10_1556_2054_2021_00157 crossref_primary_10_1177_02698811241254831 crossref_primary_10_1007_s00213_021_05857_0 crossref_primary_10_1016_j_expneurol_2022_114148 crossref_primary_10_1093_nc_niae038 crossref_primary_10_1016_j_neuropharm_2025_110402 crossref_primary_10_1001_jamapsychiatry_2025_0044 crossref_primary_10_3389_fpsyt_2024_1217102 crossref_primary_10_1038_s41386_022_01479_y crossref_primary_10_1016_j_biopha_2023_115775 crossref_primary_10_1038_s41597_022_01822_4 crossref_primary_10_1038_s41386_023_01588_2 crossref_primary_10_1080_02791072_2022_2125467 crossref_primary_10_1002_advs_202413786 crossref_primary_10_1038_s41386_024_01809_2 crossref_primary_10_1016_j_neubiorev_2022_104706 crossref_primary_10_1080_02791072_2022_2047842 crossref_primary_10_1177_02698811241301216 crossref_primary_10_1007_s00213_021_05978_6 crossref_primary_10_1038_s41398_022_02039_0 crossref_primary_10_1055_a_1486_7386 crossref_primary_10_3389_fnins_2022_832375 crossref_primary_10_1177_02698811231200019 crossref_primary_10_1177_02698811241303599 crossref_primary_10_1038_s41380_022_01832_z crossref_primary_10_1016_j_nlm_2021_107467 crossref_primary_10_3390_brainsci14030248 crossref_primary_10_1007_s00213_022_06170_0 crossref_primary_10_1038_s41598_024_65391_9 crossref_primary_10_1186_s40814_024_01449_9 crossref_primary_10_1016_j_biopsych_2022_10_021 crossref_primary_10_1007_s40263_023_01044_1 crossref_primary_10_1016_j_biopsych_2023_03_013 crossref_primary_10_1038_s41398_024_03013_8 |
Cites_doi | 10.1001/jama.2013.281053 10.1590/S1984-82502010000400011 10.1016/j.biopsych.2014.11.015 10.1021/acsptsci.0c00099 10.1177/0269881120940937 10.1093/ijnp/pyz029 10.1017/S0012162201001384 10.1097/JCP.0000000000000941 10.1177/0269881114568040 10.1016/S0893-133X(02)00343-3 10.1016/j.edurev.2010.12.001 10.1016/j.peh.2019.01.001 10.1111/bcp.13918 10.1002/cpt.2057 10.1001/archneurpsyc.1958.02340020088016 10.1097/NMD.0000000000000113 10.2174/138161208786549344 10.1371/journal.pone.0211023 10.1111/j.1530-0277.2001.tb02248.x 10.1016/j.biopsych.2019.05.019 10.1038/nrn2884 10.1007/s00213-018-5119-x 10.4088/JCP.v67n1110 10.1523/JNEUROSCI.1088-12.2012 10.1371/journal.pone.0012412 10.1007/s00213-016-4453-0 10.1177/2045125316638008 10.1038/s41386-019-0569-3 10.1177/0269881114555249 10.1016/j.drugalcdep.2012.11.010 10.3758/BF03203313 10.1016/j.euroneuro.2019.06.003 10.1017/S0033291715002901 10.1177/1455072517753339 10.1016/j.neuropsychologia.2007.02.019 10.1186/s12954-019-0308-4 10.3758/BF03200977 10.1007/BF00413239 10.1038/sj.npp.1300637 10.1097/00004583-199912000-00006 10.1038/npp.2016.82 10.3389/fnhum.2016.00269 |
ContentType | Journal Article |
Copyright | 2020 Copyright © 2020. Published by Elsevier B.V. |
Copyright_xml | – notice: 2020 – notice: Copyright © 2020. Published by Elsevier B.V. |
DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 ADTOC UNPAY |
DOI | 10.1016/j.euroneuro.2020.10.002 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-7862 |
EndPage | 91 |
ExternalDocumentID | 10.1016/j.euroneuro.2020.10.002 33082016 10_1016_j_euroneuro_2020_10_002 S0924977X20309111 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29G 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM 9JO AABNK AADFP AAEDT AAEDW AAGJA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABFRF ABIVO ABJNI ABMAC ABMZM ABOYX ABWVN ABXDB ABZDS ACDAQ ACGFO ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ACXNI ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRLJ AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDW HMK HMO HMQ HMT HVGLF HZ~ IHE J1W KOM LX8 M29 M2V M34 M41 MO0 MOBAO N9A O-L O9- OAUVE OGGZJ OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SPT SSB SSH SSN SSP SSY SSZ T5K UNMZH WUQ XPP Z5R ~G- 6I. AACTN AADPK AAFTH AAIAV AATCM ABLVK ABYKQ AFCTW AFKWA AFYLN AJBFU AJOXV AMFUW EFLBG LCYCR RIG AAYXX ACLOT CITATION ~HD NPM 7X8 ADTOC UNPAY |
ID | FETCH-LOGICAL-c476t-aa531d737d8f8975419b456055a03e46d81a01f139e357fd0a6c0ee8ff1e55d43 |
IEDL.DBID | .~1 |
ISSN | 0924-977X 1873-7862 |
IngestDate | Tue Aug 19 21:37:12 EDT 2025 Sun Sep 28 11:10:13 EDT 2025 Wed Feb 19 02:29:50 EST 2025 Thu Apr 24 23:01:08 EDT 2025 Wed Oct 01 03:11:39 EDT 2025 Fri Feb 23 02:46:13 EST 2024 Tue Aug 26 16:32:11 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Psychedelic experience Mood LSD Microdose Healthy Attention |
Language | English |
License | This is an open access article under the CC BY license. Copyright © 2020. Published by Elsevier B.V. cc-by |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c476t-aa531d737d8f8975419b456055a03e46d81a01f139e357fd0a6c0ee8ff1e55d43 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0924977X20309111 |
PMID | 33082016 |
PQID | 2452977908 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | unpaywall_primary_10_1016_j_euroneuro_2020_10_002 proquest_miscellaneous_2452977908 pubmed_primary_33082016 crossref_citationtrail_10_1016_j_euroneuro_2020_10_002 crossref_primary_10_1016_j_euroneuro_2020_10_002 elsevier_sciencedirect_doi_10_1016_j_euroneuro_2020_10_002 elsevier_clinicalkey_doi_10_1016_j_euroneuro_2020_10_002 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | December 2020 2020-12-00 20201201 |
PublicationDateYYYYMMDD | 2020-12-01 |
PublicationDate_xml | – month: 12 year: 2020 text: December 2020 |
PublicationDecade | 2020 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | European neuropsychopharmacology |
PublicationTitleAlternate | Eur Neuropsychopharmacol |
PublicationYear | 2020 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Dinges, Powell (bib0009) 1985; 17 Lea, Amada, Jungaberle (bib0037) 2019 Anderson, Petranker, Christopher, Rosenbaum, Weissman, Dinh-Williams, Hapke (bib0001) 2019; 16 DIMS, 2019. Jaarbericht 2018. (Accessed 18 May 2020). Retrieved from Utrecht Hupli, Berning, Zhuparris, Fadiman (bib0025) 2019; 6 Moreno, Wiegand, Taitano, Delgado (bib0044) 2006; 67 Vollenweider, Kometer (bib0056) 2010; 11 Gasser, Kirchner, Passie (bib0015) 2015; 29 Johnstad (bib0032) 2018; 35 Holze, Duthaler, Vizeli, Müller, Borgwardt, Liechti (bib0022) 2019; 85 Glatter, R., 2015. LSD microdosing: the new job enhancer in Silicon Valley. (Accessed 30 November 2018). Retrieved from Brown, Prescott (bib0004) 2014 (bib0059) 2013; 310 Bershad, Schepers, Bremmer, Lee, de Wit (bib0003) 2019; 86 Winstock, A.R., Barrett, M.J., Ferris, J.A., & Maier, L.J., 2017. Global drug survey (GDS) 2017. Global overview and highlights. (Accessed 24 June 2019). Retrieved from Johnson, Robertson, Kelly, Silk, Barry, Dáibhis, Gallagher (bib0031) 2007; 45 Gasser, Holstein, Michel, Doblin, Yazar-Klosinski, Passie, Brenneisen (bib0014) 2014; 202 Ramaekers, Hutten, Mason, Dolder, Theunissen, Holze, Kuypers (bib0048) 2020 Liechti, Dolder, Schmid (bib0038) 2017; 234 Winsberg, Comings (bib0057) 1999; 38 Thethirdwave, 2018. Microdosing. (Accessed 30 November 2018). Retrieved from Holdstock, de Wit (bib0021) 2001; 25 Studerus, Gamma, Vollenweider (bib0052) 2010; 5 Majić, Schmidt, Gallinat (bib0040) 2015; 29 van der Meulen, Wijnberg, Hollander, van de Hoofdakker (bib0045) 1980 Bershad, Preller, Lee, Keedy, Wren-Jarvis, Bremmer, de Wit (bib0002) 2019; 5 Ilgin, Senol, Gucuyener, Gokcora, Atavci, Sener (bib0029) 2001; 43 Jaeger (bib0030) 2018; 38 Kuypers, Livia, Erritzoe, Knudsen, Nichols, Nichols, Nutt (bib0035) 2019 . Carhart-Harris, Kaelen, Bolstridge, Williams, Williams, Underwood, Nutt (bib0005) 2016; 46 Hutten, Mason, Dolder, Kuypers (bib0026) 2019; 22 Polito, Stevenson (bib0047) 2019; 14 Szigeti (bib0053) 2020 De Wit, Enggasser, Richards (bib0006) 2002; 27 Family, Maillet, Williams, Krediet, Carhart-Harris, Williams, Raz (bib0013) 2019 Santos, G., Osorio, Crippa, Riba, Zuardi, Hallak (bib0011) 2016; 6 Mirsky, Kornetsky (bib0043) 1964; 5 Hutten, Mason, Dolder, Theunissen, Holze, Liechti, Kuypers (bib0027) 2020 McLeod, Griffiths, Bigelow, Yingling (bib0042) 1982; 14 Kuypers, K.P.C., Hutten, N.R.P.W., Mason, N.L., Dolder, P.C., Theunissen, E.L., Holze, F., Ramaekers, J.G., 2020. A low dose of LSD has minimal to no effects on creative processes and empathy but increases self-rated content in written stories. (Submitted). Richardson (bib0049) 2011; 6 Sahakian, B., d'Angelo, C., & Savulich, G., 2018. `Microdosing' LSD is not just a Silicon Valley trend - it is spreading to other workplaces. (Accessed 5 May 2019). Retrieved from Holze, Vizeli, Müller, Ley, Duerig, Varghese, Liechti (bib0024) 2020; 45 Marinho, Leite (bib0041) 2010; 46 Yanakieva, Polychroni, Family, Williams, Luke, Terhune (bib0060) 2019; 236 Hutten, Steenbergen, Colzato, Hommel, Theunissen, Ramaekers, Kuypers (bib0028) 2019; 29 Holze, Liechti, Hutten, Mason, Dolder, Duthaler, Kuypers (bib0023) 2020 Nour, Evans, Nutt, Carhart-Harris (bib0046) 2016; 10 Fadiman (bib0012) 2011 Schmid, Enzler, Gasser, Grouzmann, Preller, Vollenweider, Liechti (bib0051) 2015; 78 Greiner, Burch, Edelberg (bib0017) 1958; 79 Lott, Kim, Cook Jr, de Wit (bib0039) 2005; 30 Landolt (bib0036) 2008; 14 Dolder, Schmid, Müller, Borgwardt, Liechti (bib0010) 2016; 41 de Wit, Watson, Harsay, Cohen, van de Vijver, Ridderinkhof (bib0007) 2012; 32 Hallock, Dean, Knecht, Spencer, Taverna (bib0018) 2013; 130 10.1016/j.euroneuro.2020.10.002_bib0034 Anderson (10.1016/j.euroneuro.2020.10.002_bib0001) 2019; 16 Holze (10.1016/j.euroneuro.2020.10.002_bib0022) 2019; 85 Gasser (10.1016/j.euroneuro.2020.10.002_bib0015) 2015; 29 Ramaekers (10.1016/j.euroneuro.2020.10.002_bib0048) 2020 Winsberg (10.1016/j.euroneuro.2020.10.002_bib0057) 1999; 38 Hutten (10.1016/j.euroneuro.2020.10.002_bib0028) 2019; 29 Landolt (10.1016/j.euroneuro.2020.10.002_bib0036) 2008; 14 Dolder (10.1016/j.euroneuro.2020.10.002_bib0010) 2016; 41 Greiner (10.1016/j.euroneuro.2020.10.002_bib0017) 1958; 79 Santos (10.1016/j.euroneuro.2020.10.002_bib0011) 2016; 6 Ilgin (10.1016/j.euroneuro.2020.10.002_bib0029) 2001; 43 Carhart-Harris (10.1016/j.euroneuro.2020.10.002_bib0005) 2016; 46 Jaeger (10.1016/j.euroneuro.2020.10.002_bib0030) 2018; 38 Nour (10.1016/j.euroneuro.2020.10.002_bib0046) 2016; 10 Hallock (10.1016/j.euroneuro.2020.10.002_bib0018) 2013; 130 Szigeti (10.1016/j.euroneuro.2020.10.002_bib0053) 2020 Moreno (10.1016/j.euroneuro.2020.10.002_bib0044) 2006; 67 Bershad (10.1016/j.euroneuro.2020.10.002_bib0003) 2019; 86 Mirsky (10.1016/j.euroneuro.2020.10.002_bib0043) 1964; 5 Hutten (10.1016/j.euroneuro.2020.10.002_bib0026) 2019; 22 Johnstad (10.1016/j.euroneuro.2020.10.002_bib0032) 2018; 35 de Wit (10.1016/j.euroneuro.2020.10.002_bib0007) 2012; 32 De Wit (10.1016/j.euroneuro.2020.10.002_bib0006) 2002; 27 Hutten (10.1016/j.euroneuro.2020.10.002_bib0027) 2020 10.1016/j.euroneuro.2020.10.002_bib0054 Schmid (10.1016/j.euroneuro.2020.10.002_bib0051) 2015; 78 10.1016/j.euroneuro.2020.10.002_bib0016 Hupli (10.1016/j.euroneuro.2020.10.002_bib0025) 2019; 6 10.1016/j.euroneuro.2020.10.002_bib0058 Holze (10.1016/j.euroneuro.2020.10.002_bib0023) 2020 Marinho (10.1016/j.euroneuro.2020.10.002_bib0041) 2010; 46 Yanakieva (10.1016/j.euroneuro.2020.10.002_bib0060) 2019; 236 Gasser (10.1016/j.euroneuro.2020.10.002_bib0014) 2014; 202 Kuypers (10.1016/j.euroneuro.2020.10.002_bib0035) 2019 Majić (10.1016/j.euroneuro.2020.10.002_bib0040) 2015; 29 Lea (10.1016/j.euroneuro.2020.10.002_bib0037) 2019 Richardson (10.1016/j.euroneuro.2020.10.002_bib0049) 2011; 6 Johnson (10.1016/j.euroneuro.2020.10.002_bib0031) 2007; 45 Polito (10.1016/j.euroneuro.2020.10.002_bib0047) 2019; 14 Brown (10.1016/j.euroneuro.2020.10.002_bib0004) 2014 10.1016/j.euroneuro.2020.10.002_bib0050 Holze (10.1016/j.euroneuro.2020.10.002_bib0024) 2020; 45 Fadiman (10.1016/j.euroneuro.2020.10.002_bib0012) 2011 Vollenweider (10.1016/j.euroneuro.2020.10.002_bib0056) 2010; 11 Bershad (10.1016/j.euroneuro.2020.10.002_bib0002) 2019; 5 10.1016/j.euroneuro.2020.10.002_bib0008 Family (10.1016/j.euroneuro.2020.10.002_bib0013) 2019 (10.1016/j.euroneuro.2020.10.002_bib0059) 2013; 310 Dinges (10.1016/j.euroneuro.2020.10.002_bib0009) 1985; 17 Studerus (10.1016/j.euroneuro.2020.10.002_bib0052) 2010; 5 Lott (10.1016/j.euroneuro.2020.10.002_bib0039) 2005; 30 Liechti (10.1016/j.euroneuro.2020.10.002_bib0038) 2017; 234 Holdstock (10.1016/j.euroneuro.2020.10.002_bib0021) 2001; 25 McLeod (10.1016/j.euroneuro.2020.10.002_bib0042) 1982; 14 van der Meulen (10.1016/j.euroneuro.2020.10.002_bib0045) 1980 |
References_xml | – volume: 234 start-page: 1499 year: 2017 end-page: 1510 ident: bib0038 article-title: Alterations of consciousness and mystical-type experiences after acute LSD in humans publication-title: Psychopharmacol. Berl. – volume: 16 start-page: 43 year: 2019 ident: bib0001 article-title: Psychedelic microdosing benefits and challenges: an empirical codebook publication-title: Harm Reduct. J. – volume: 22 start-page: 426 year: 2019 end-page: 434 ident: bib0026 article-title: Motives and side-effects of microdosing with psychedelics among users publication-title: Int. J. Neuropsychopharmacol. – volume: 310 start-page: 2191 year: 2013 end-page: 2194 ident: bib0059 article-title: World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects publication-title: JAMA – volume: 17 start-page: 652 year: 1985 end-page: 655 ident: bib0009 article-title: Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations publication-title: Behav. Res. Methods Instrum. Comput. – year: 2020 ident: bib0048 article-title: A low dose of lysergic acid diethylamide (LSD) decreases pain perception in healthy volunteers publication-title: J. Psychopharmacol. – volume: 78 start-page: 544 year: 2015 end-page: 553 ident: bib0051 article-title: Acute effects of lysergic acid diethylamide in healthy subjects publication-title: Biol. Psychiatry – volume: 46 start-page: 1379 year: 2016 end-page: 1390 ident: bib0005 article-title: The paradoxical psychological effects of lysergic acid diethylamide (LSD) publication-title: Psychol. Med. – volume: 46 start-page: 695 year: 2010 end-page: 703 ident: bib0041 article-title: Quantification of LSD in illicit samples by high performance liquid chromatography publication-title: Braz. J. Pharm. Sci. – volume: 130 start-page: 245 year: 2013 end-page: 248 ident: bib0018 article-title: A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students publication-title: Drug Alcohol Depend. – reference: Thethirdwave, 2018. Microdosing. (Accessed 30 November 2018). Retrieved from – volume: 41 start-page: 2638 year: 2016 ident: bib0010 article-title: LSD acutely impairs fear recognition and enhances emotional empathy and sociality publication-title: Neuropsychopharmacology – start-page: 1 year: 2019 end-page: 19 ident: bib0035 article-title: Microdosing psychedelics: more questions than answers? An overview and suggestions for future research publication-title: J. Psychopharmacol. – volume: 14 year: 2019 ident: bib0047 article-title: A systematic study of microdosing psychedelics publication-title: PLoS ONE – volume: 79 start-page: 208 year: 1958 end-page: 210 ident: bib0017 article-title: Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum publication-title: AMA Arch. Neurol. Psychiatry – volume: 5 start-page: e12412 year: 2010 ident: bib0052 article-title: Psychometric evaluation of the altered states of consciousness rating scale (OAV) publication-title: PLoS ONE – year: 2020 ident: bib0053 article-title: Beyond the placebo? An exploration of psychedelics microdosing with self-blinding methodology [abstract] publication-title: Proceedings of the Interdisciplinary Conference on Psychedelic Research – volume: 27 start-page: 813 year: 2002 end-page: 825 ident: bib0006 article-title: Acute administration of d-amphetamine decreases impulsivity in healthy volunteers publication-title: Neuropsychopharmacology – volume: 67 start-page: 1735 year: 2006 end-page: 1740 ident: bib0044 article-title: Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder publication-title: J. Clin. Psychiatry – volume: 29 start-page: 813 year: 2019 end-page: 824 ident: bib0028 article-title: Cocaine enhances figural, but impairs verbal ‘flexible'divergent thinking publication-title: Eur. Neuropsychopharmacol. – year: 2020 ident: bib0023 article-title: Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants publication-title: Clin Pharmacol & Ther – volume: 38 start-page: 513 year: 2018 end-page: 519 ident: bib0030 article-title: Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing publication-title: J. Clin. Psychopharmacol. – volume: 45 start-page: 2234 year: 2007 end-page: 2245 ident: bib0031 article-title: Dissociation in performance of children with ADHD and high-functioning autism on a task of sustained attention publication-title: Neuropsychologia – volume: 86 start-page: 792 year: 2019 end-page: 800 ident: bib0003 article-title: Acute subjective and behavioral effects of microdoses of LSD in healthy human volunteers publication-title: Biol. Psychiatry – volume: 43 start-page: 755 year: 2001 end-page: 760 ident: bib0029 article-title: Is increased D2 receptor availability associated with response to stimulant medication in ADHD publication-title: Dev. Med. Child Neurol. – volume: 14 start-page: 3396 year: 2008 end-page: 3407 ident: bib0036 article-title: Genotype-dependent differences in sleep, vigilance, and response to stimulants publication-title: Curr. Pharm. Des. – volume: 6 start-page: 129 year: 2019 end-page: 138 ident: bib0025 article-title: Descriptive assemblage of psychedelic microdosing: netnographic study of Youtube™ videos and on-going research projects publication-title: Perform. Enhanc. Health – year: 1980 ident: bib0045 article-title: Measurements of sleep quality publication-title: Proceedings of the European Sleep Conference – start-page: 1 year: 2019 end-page: 12 ident: bib0037 article-title: Psychedelic microdosing: a subreddit analysis publication-title: J. Psychoact. Drugs – reference: DIMS, 2019. Jaarbericht 2018. (Accessed 18 May 2020). Retrieved from Utrecht: – volume: 6 start-page: 135 year: 2011 end-page: 147 ident: bib0049 article-title: Eta squared and partial eta squared as measures of effect size in educational research publication-title: Educ. Res. Rev. – volume: 32 start-page: 12066 year: 2012 end-page: 12075 ident: bib0007 article-title: Corticostriatal connectivity underlies individual differences in the balance between habitual and goal-directed action control publication-title: J. Neurosci. – volume: 45 start-page: 462 year: 2020 end-page: 471 ident: bib0024 article-title: Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects publication-title: Neuropsychopharmacology – volume: 5 start-page: 461 year: 2019 end-page: 467 ident: bib0002 article-title: Preliminary report on the effects of a low dose of LSD on resting state amygdalar functional connectivity publication-title: Biol. Psychiatry Cogn. Neurosci. Neuroimaging – volume: 5 start-page: 161 year: 1964 end-page: 177 ident: bib0043 article-title: On the dissimilar effects of drugs on the digit symbol substitution and continuous performance tests publication-title: Psychopharmacologia – volume: 30 start-page: 602 year: 2005 ident: bib0039 article-title: Dopamine transporter gene associated with diminished subjective response to amphetamine publication-title: Neuropsychopharmacology – volume: 6 start-page: 193 year: 2016 end-page: 213 ident: bib0011 article-title: Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years publication-title: Ther. Adv. Psychopharmacol. – volume: 35 start-page: 39 year: 2018 end-page: 51 ident: bib0032 article-title: Powerful substances in tiny amounts: an interview study of psychedelic microdosing publication-title: Nord. Stud. Alcohol Drugs – reference: Kuypers, K.P.C., Hutten, N.R.P.W., Mason, N.L., Dolder, P.C., Theunissen, E.L., Holze, F., Ramaekers, J.G., 2020. A low dose of LSD has minimal to no effects on creative processes and empathy but increases self-rated content in written stories. (Submitted). – volume: 29 start-page: 241 year: 2015 end-page: 253 ident: bib0040 article-title: Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? publication-title: J. Psychopharmacol. – volume: 29 start-page: 57 year: 2015 end-page: 68 ident: bib0015 article-title: LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects publication-title: J. Psychopharmacol. – reference: Winstock, A.R., Barrett, M.J., Ferris, J.A., & Maier, L.J., 2017. Global drug survey (GDS) 2017. Global overview and highlights. (Accessed 24 June 2019). Retrieved from – volume: 236 start-page: 1159 year: 2019 end-page: 1170 ident: bib0060 article-title: The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial publication-title: Psychopharmacol. Berl. – start-page: 1 year: 2019 end-page: 13 ident: bib0013 article-title: Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers publication-title: Psychopharmacol. Berl. – volume: 14 start-page: 463 year: 1982 end-page: 466 ident: bib0042 article-title: An automated version of the digit symbol substitution test (DSST) publication-title: Behav. Res. Methods Instrum. – year: 2011 ident: bib0012 article-title: The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys – year: 2020 ident: bib0027 article-title: Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers publication-title: ACS Pharmacol. Transl. Sci. – year: 2014 ident: bib0004 article-title: Applied Mixed Models in Medicine – volume: 10 start-page: 269 year: 2016 ident: bib0046 article-title: Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI) publication-title: Front. Hum. Neurosci. – reference: . – reference: Glatter, R., 2015. LSD microdosing: the new job enhancer in Silicon Valley. (Accessed 30 November 2018). Retrieved from – volume: 38 start-page: 1474 year: 1999 end-page: 1477 ident: bib0057 article-title: Association of the dopamine transporter gene (DAT1) with poor methylphenidate response publication-title: J. Am. Acad. Child Adolesc. Psychiatry – volume: 25 start-page: 540 year: 2001 end-page: 548 ident: bib0021 article-title: Individual differences in responses to ethanol and d-amphetamine: a within-subject study publication-title: Alcohol. Clin. Exp. Res. – volume: 85 start-page: 1474 year: 2019 end-page: 1483 ident: bib0022 article-title: Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects publication-title: Br. J. Clin. Pharmacol – volume: 11 start-page: 642 year: 2010 ident: bib0056 article-title: The neurobiology of psychedelic drugs: implications for the treatment of mood disorders publication-title: Nat. Rev. Neurosci. – volume: 202 start-page: 513 year: 2014 ident: bib0014 article-title: Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases publication-title: J. Nerv. Ment. Dis. – reference: Sahakian, B., d'Angelo, C., & Savulich, G., 2018. `Microdosing' LSD is not just a Silicon Valley trend - it is spreading to other workplaces. (Accessed 5 May 2019). Retrieved from – volume: 310 start-page: 2191 issue: 20 year: 2013 ident: 10.1016/j.euroneuro.2020.10.002_bib0059 article-title: World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects publication-title: JAMA doi: 10.1001/jama.2013.281053 – volume: 46 start-page: 695 year: 2010 ident: 10.1016/j.euroneuro.2020.10.002_bib0041 article-title: Quantification of LSD in illicit samples by high performance liquid chromatography publication-title: Braz. J. Pharm. Sci. doi: 10.1590/S1984-82502010000400011 – volume: 78 start-page: 544 issue: 8 year: 2015 ident: 10.1016/j.euroneuro.2020.10.002_bib0051 article-title: Acute effects of lysergic acid diethylamide in healthy subjects publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2014.11.015 – year: 2020 ident: 10.1016/j.euroneuro.2020.10.002_bib0027 article-title: Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers publication-title: ACS Pharmacol. Transl. Sci. doi: 10.1021/acsptsci.0c00099 – ident: 10.1016/j.euroneuro.2020.10.002_bib0034 – year: 2020 ident: 10.1016/j.euroneuro.2020.10.002_bib0048 article-title: A low dose of lysergic acid diethylamide (LSD) decreases pain perception in healthy volunteers publication-title: J. Psychopharmacol. doi: 10.1177/0269881120940937 – volume: 22 start-page: 426 issue: 7 year: 2019 ident: 10.1016/j.euroneuro.2020.10.002_bib0026 article-title: Motives and side-effects of microdosing with psychedelics among users publication-title: Int. J. Neuropsychopharmacol. doi: 10.1093/ijnp/pyz029 – volume: 43 start-page: 755 issue: 11 year: 2001 ident: 10.1016/j.euroneuro.2020.10.002_bib0029 article-title: Is increased D2 receptor availability associated with response to stimulant medication in ADHD publication-title: Dev. Med. Child Neurol. doi: 10.1017/S0012162201001384 – volume: 5 start-page: 461 issue: 4 year: 2019 ident: 10.1016/j.euroneuro.2020.10.002_bib0002 article-title: Preliminary report on the effects of a low dose of LSD on resting state amygdalar functional connectivity publication-title: Biol. Psychiatry Cogn. Neurosci. Neuroimaging – volume: 38 start-page: 513 issue: 5 year: 2018 ident: 10.1016/j.euroneuro.2020.10.002_bib0030 article-title: Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing publication-title: J. Clin. Psychopharmacol. doi: 10.1097/JCP.0000000000000941 – volume: 29 start-page: 241 issue: 3 year: 2015 ident: 10.1016/j.euroneuro.2020.10.002_bib0040 article-title: Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? publication-title: J. Psychopharmacol. doi: 10.1177/0269881114568040 – year: 2014 ident: 10.1016/j.euroneuro.2020.10.002_bib0004 – year: 2020 ident: 10.1016/j.euroneuro.2020.10.002_bib0053 article-title: Beyond the placebo? An exploration of psychedelics microdosing with self-blinding methodology [abstract] – volume: 27 start-page: 813 issue: 5 year: 2002 ident: 10.1016/j.euroneuro.2020.10.002_bib0006 article-title: Acute administration of d-amphetamine decreases impulsivity in healthy volunteers publication-title: Neuropsychopharmacology doi: 10.1016/S0893-133X(02)00343-3 – volume: 6 start-page: 135 issue: 2 year: 2011 ident: 10.1016/j.euroneuro.2020.10.002_bib0049 article-title: Eta squared and partial eta squared as measures of effect size in educational research publication-title: Educ. Res. Rev. doi: 10.1016/j.edurev.2010.12.001 – ident: 10.1016/j.euroneuro.2020.10.002_bib0008 – volume: 6 start-page: 129 issue: 3 year: 2019 ident: 10.1016/j.euroneuro.2020.10.002_bib0025 article-title: Descriptive assemblage of psychedelic microdosing: netnographic study of Youtube™ videos and on-going research projects publication-title: Perform. Enhanc. Health doi: 10.1016/j.peh.2019.01.001 – volume: 85 start-page: 1474 issue: 7 year: 2019 ident: 10.1016/j.euroneuro.2020.10.002_bib0022 article-title: Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects publication-title: Br. J. Clin. Pharmacol doi: 10.1111/bcp.13918 – ident: 10.1016/j.euroneuro.2020.10.002_bib0054 – start-page: 1 year: 2019 ident: 10.1016/j.euroneuro.2020.10.002_bib0013 article-title: Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers publication-title: Psychopharmacol. Berl. – year: 2020 ident: 10.1016/j.euroneuro.2020.10.002_bib0023 article-title: Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants publication-title: Clin Pharmacol & Ther doi: 10.1002/cpt.2057 – volume: 79 start-page: 208 issue: 2 year: 1958 ident: 10.1016/j.euroneuro.2020.10.002_bib0017 article-title: Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum publication-title: AMA Arch. Neurol. Psychiatry doi: 10.1001/archneurpsyc.1958.02340020088016 – ident: 10.1016/j.euroneuro.2020.10.002_bib0058 – ident: 10.1016/j.euroneuro.2020.10.002_bib0050 – volume: 202 start-page: 513 issue: 7 year: 2014 ident: 10.1016/j.euroneuro.2020.10.002_bib0014 article-title: Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases publication-title: J. Nerv. Ment. Dis. doi: 10.1097/NMD.0000000000000113 – start-page: 1 year: 2019 ident: 10.1016/j.euroneuro.2020.10.002_bib0035 article-title: Microdosing psychedelics: more questions than answers? An overview and suggestions for future research publication-title: J. Psychopharmacol. – volume: 14 start-page: 3396 issue: 32 year: 2008 ident: 10.1016/j.euroneuro.2020.10.002_bib0036 article-title: Genotype-dependent differences in sleep, vigilance, and response to stimulants publication-title: Curr. Pharm. Des. doi: 10.2174/138161208786549344 – volume: 14 issue: 2 year: 2019 ident: 10.1016/j.euroneuro.2020.10.002_bib0047 article-title: A systematic study of microdosing psychedelics publication-title: PLoS ONE doi: 10.1371/journal.pone.0211023 – volume: 25 start-page: 540 issue: 4 year: 2001 ident: 10.1016/j.euroneuro.2020.10.002_bib0021 article-title: Individual differences in responses to ethanol and d-amphetamine: a within-subject study publication-title: Alcohol. Clin. Exp. Res. doi: 10.1111/j.1530-0277.2001.tb02248.x – volume: 86 start-page: 792 issue: 10 year: 2019 ident: 10.1016/j.euroneuro.2020.10.002_bib0003 article-title: Acute subjective and behavioral effects of microdoses of LSD in healthy human volunteers publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2019.05.019 – volume: 11 start-page: 642 issue: 9 year: 2010 ident: 10.1016/j.euroneuro.2020.10.002_bib0056 article-title: The neurobiology of psychedelic drugs: implications for the treatment of mood disorders publication-title: Nat. Rev. Neurosci. doi: 10.1038/nrn2884 – volume: 236 start-page: 1159 issue: 4 year: 2019 ident: 10.1016/j.euroneuro.2020.10.002_bib0060 article-title: The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial publication-title: Psychopharmacol. Berl. doi: 10.1007/s00213-018-5119-x – volume: 67 start-page: 1735 issue: 11 year: 2006 ident: 10.1016/j.euroneuro.2020.10.002_bib0044 article-title: Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder publication-title: J. Clin. Psychiatry doi: 10.4088/JCP.v67n1110 – volume: 32 start-page: 12066 issue: 35 year: 2012 ident: 10.1016/j.euroneuro.2020.10.002_bib0007 article-title: Corticostriatal connectivity underlies individual differences in the balance between habitual and goal-directed action control publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.1088-12.2012 – volume: 5 start-page: e12412 issue: 8 year: 2010 ident: 10.1016/j.euroneuro.2020.10.002_bib0052 article-title: Psychometric evaluation of the altered states of consciousness rating scale (OAV) publication-title: PLoS ONE doi: 10.1371/journal.pone.0012412 – ident: 10.1016/j.euroneuro.2020.10.002_bib0016 – volume: 234 start-page: 1499 issue: 9–10 year: 2017 ident: 10.1016/j.euroneuro.2020.10.002_bib0038 article-title: Alterations of consciousness and mystical-type experiences after acute LSD in humans publication-title: Psychopharmacol. Berl. doi: 10.1007/s00213-016-4453-0 – volume: 6 start-page: 193 issue: 3 year: 2016 ident: 10.1016/j.euroneuro.2020.10.002_bib0011 article-title: Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years publication-title: Ther. Adv. Psychopharmacol. doi: 10.1177/2045125316638008 – start-page: 1 year: 2019 ident: 10.1016/j.euroneuro.2020.10.002_bib0037 article-title: Psychedelic microdosing: a subreddit analysis publication-title: J. Psychoact. Drugs – volume: 45 start-page: 462 issue: 3 year: 2020 ident: 10.1016/j.euroneuro.2020.10.002_bib0024 article-title: Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects publication-title: Neuropsychopharmacology doi: 10.1038/s41386-019-0569-3 – volume: 29 start-page: 57 issue: 1 year: 2015 ident: 10.1016/j.euroneuro.2020.10.002_bib0015 article-title: LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects publication-title: J. Psychopharmacol. doi: 10.1177/0269881114555249 – volume: 130 start-page: 245 issue: 1–3 year: 2013 ident: 10.1016/j.euroneuro.2020.10.002_bib0018 article-title: A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students publication-title: Drug Alcohol Depend. doi: 10.1016/j.drugalcdep.2012.11.010 – volume: 14 start-page: 463 issue: 5 year: 1982 ident: 10.1016/j.euroneuro.2020.10.002_bib0042 article-title: An automated version of the digit symbol substitution test (DSST) publication-title: Behav. Res. Methods Instrum. doi: 10.3758/BF03203313 – volume: 29 start-page: 813 issue: 7 year: 2019 ident: 10.1016/j.euroneuro.2020.10.002_bib0028 article-title: Cocaine enhances figural, but impairs verbal ‘flexible'divergent thinking publication-title: Eur. Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2019.06.003 – volume: 46 start-page: 1379 issue: 7 year: 2016 ident: 10.1016/j.euroneuro.2020.10.002_bib0005 article-title: The paradoxical psychological effects of lysergic acid diethylamide (LSD) publication-title: Psychol. Med. doi: 10.1017/S0033291715002901 – volume: 35 start-page: 39 issue: 1 year: 2018 ident: 10.1016/j.euroneuro.2020.10.002_bib0032 article-title: Powerful substances in tiny amounts: an interview study of psychedelic microdosing publication-title: Nord. Stud. Alcohol Drugs doi: 10.1177/1455072517753339 – volume: 45 start-page: 2234 issue: 10 year: 2007 ident: 10.1016/j.euroneuro.2020.10.002_bib0031 article-title: Dissociation in performance of children with ADHD and high-functioning autism on a task of sustained attention publication-title: Neuropsychologia doi: 10.1016/j.neuropsychologia.2007.02.019 – volume: 16 start-page: 43 issue: 1 year: 2019 ident: 10.1016/j.euroneuro.2020.10.002_bib0001 article-title: Psychedelic microdosing benefits and challenges: an empirical codebook publication-title: Harm Reduct. J. doi: 10.1186/s12954-019-0308-4 – volume: 17 start-page: 652 issue: 6 year: 1985 ident: 10.1016/j.euroneuro.2020.10.002_bib0009 article-title: Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations publication-title: Behav. Res. Methods Instrum. Comput. doi: 10.3758/BF03200977 – volume: 5 start-page: 161 issue: 3 year: 1964 ident: 10.1016/j.euroneuro.2020.10.002_bib0043 article-title: On the dissimilar effects of drugs on the digit symbol substitution and continuous performance tests publication-title: Psychopharmacologia doi: 10.1007/BF00413239 – volume: 30 start-page: 602 issue: 3 year: 2005 ident: 10.1016/j.euroneuro.2020.10.002_bib0039 article-title: Dopamine transporter gene associated with diminished subjective response to amphetamine publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1300637 – year: 2011 ident: 10.1016/j.euroneuro.2020.10.002_bib0012 – year: 1980 ident: 10.1016/j.euroneuro.2020.10.002_bib0045 article-title: Measurements of sleep quality – volume: 38 start-page: 1474 issue: 12 year: 1999 ident: 10.1016/j.euroneuro.2020.10.002_bib0057 article-title: Association of the dopamine transporter gene (DAT1) with poor methylphenidate response publication-title: J. Am. Acad. Child Adolesc. Psychiatry doi: 10.1097/00004583-199912000-00006 – volume: 41 start-page: 2638 issue: 11 year: 2016 ident: 10.1016/j.euroneuro.2020.10.002_bib0010 article-title: LSD acutely impairs fear recognition and enhances emotional empathy and sociality publication-title: Neuropsychopharmacology doi: 10.1038/npp.2016.82 – volume: 10 start-page: 269 year: 2016 ident: 10.1016/j.euroneuro.2020.10.002_bib0046 article-title: Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI) publication-title: Front. Hum. Neurosci. doi: 10.3389/fnhum.2016.00269 |
SSID | ssj0015339 |
Score | 2.560557 |
Snippet | •Low dose of LSD (5 and 20 mcg) enhances sustained attention.•Low dose of LSD (20 mcg) reduces speed of information processing.•Low dose of LSD affects mood... There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific... |
SourceID | unpaywall proquest pubmed crossref elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 81 |
SubjectTerms | Attention Healthy LSD Microdose Mood Psychedelic experience |
SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7C5lB6SJ9JtyRlCiGnaGNbsuXNbUkbQmnCQrOwORnZI4e2xg7dXcL2kN9eSX6k2wd5XG3GWKOR9In55huAXRmQ8DVJprjOmVBhwIYeJxYTqSyQUgvXi-D0LDqZiE_TcLoGB20tzEr-3vGwrEaF03Y0l7nAPh048cj1yGaUerA-ORuPLpyiXiCYQTNTe8WKJWfSgPUVRtc_v_S_8-hvvPkUnizKK7W8VkXx2xl0_AzG7d_X1JPvg8U8HWQ__xB2fMDwnsNGg0dxVAfQC1jT5UvYG9eC1st9PL-tz5rt4x6Ob6Wul6_g5rSqCFVJ2NCQqhJd13FUK6K8WOVYVNf4-csHpGqmZ_i1xLoEc4l2gzTTa3DoIY7QkcTSChsOfaHJWbCaeIIux15eopPFfQ2T44_nRyes6ejAMiGjOVPKLHmSXFKcx0MZCn-YGgTnhaHyuBYRxb7y_NygUs1DmZOnoszTOs5zX4chCb4JvdK46w2gzHighuSngTRXKJ6qNMoyMicyBSI3qKQPUTuvSdbInduuG0XS8tq-JZ3vE-t7-8L4vg9eZ3hVK37cbRK3gZO0Ba1mC07MbN9tetiZNpinxjL3M37fRmlidgWb6lGlrhazxOXTrZRk3IetOny7wXDuYF_UB7-L5_uO9O0jbLahN_-x0DsGvM3Td82C_QWbW0Th priority: 102 providerName: Unpaywall |
Title | Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0924977X20309111 https://dx.doi.org/10.1016/j.euroneuro.2020.10.002 https://www.ncbi.nlm.nih.gov/pubmed/33082016 https://www.proquest.com/docview/2452977908 https://doi.org/10.1016/j.euroneuro.2020.10.002 |
UnpaywallVersion | publishedVersion |
Volume | 41 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1873-7862 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0015339 issn: 1873-7862 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1873-7862 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0015339 issn: 1873-7862 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 1873-7862 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0015339 issn: 1873-7862 databaseCode: AIKHN dateStart: 19950301 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Freedom Collection 2025 customDbUrl: eissn: 1873-7862 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0015339 issn: 1873-7862 databaseCode: ACRLP dateStart: 19950301 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1873-7862 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0015339 issn: 1873-7862 databaseCode: AKRWK dateStart: 19901101 isFulltext: true providerName: Library Specific Holdings |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ba9swFD6U7mHbw9i92aWcwehTtdiSbDl9C9lKtrUhrA1kT0a25JFh7LAklLz0t08X213YoIU9GV8OWD5HR5-s73wCeC-o4qFWgkimC8JlRMkgYIokSsmcCqG524vgfBKPZ_zLPJrvwaithbG0yib3-5zusnVzpd98zf5ysehfBHbqIMSc2lWC0NX3WvUvE9Mfrjuah4UzXm-PcmKf3uF4Wf0LpxtpJorUXu3-r_xjhPobgT6E-5tqKbdXsiz_GJVOH8OjBk7i0L_xE9jT1VM4mno96u0xXt6UV62O8QinN0rV22dwfV7XCmWlsGER1RW6TcNR7mjqYl1gWV_h2cVHVPVKr3BRoa-g3KLNb8Y7Bkae4BAdxyursaHAl1o5C-J5I-iWyKsf6FRtn8Ps9NPlaEyaDRlIzkW8JlKaHqsEEyopkoGIeDjIDAALokgGTPNYJaEMwsKASs0iUahAxnmgdVIUoY4ixdkL2K_MBz8AFDmjcqDCjAozA2KZzOI8V2ZAVZQXBlT0IG6dkOaNWrndNKNMW1raz7TzXmq9Z28Y7_Ug6AyXXrDjdpOk9XLa1qOaDJqaQeV205POdCds72b8rg2p1HRqu1IjK11vVqlbDrdKkEkPXvpY6xrDmENtcQ_CLvju2tJX__O6r-GBPfNcnjewv_610W8NIltnh67LHcK94ejb2dQeP38dT8xxNpkOv_8GTvQ8ow |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED9K-tDtYXTfafdxg9GnitiWbDl9C-1Kuiah0BTyZmRLLhnGDktCyUv_9unDdhs2aGGvFgeS7nT3k-_uJ4DvPJDMV5ITQVVOmAgD0veoJLGUIgs4V8y-RTCeRMMb9nMWznbgtOmFMWWVte93Pt166_pLr97N3mI-71175urA-SwwWQLf9PfuslD75A7sDi4uh5M2maARjaPcCxgxAltlXoYCw1JH6rtiYL62v1j-EaT-BqEvYW9dLsTmThTFo8B0vg-vakSJAzfp17CjyjdwdOUoqTfHOH3osFoe4xFePZBVb97C_biqJIpSYl1IVJVo3w1HsUWri1WORXWHo-szlNVSLXFeomui3KBxcVpBGkme4ABtmVdaYV0FXyhpJYgrHUGbJS9v0RLbvoOb8x_T0yGp32QgGePRigihD63klMs4j_tc73c_1RjMC0PhUcUiGfvC83ONKxUNeS49EWWeUnGe-yoMJaPvoVPqDf8IyDMaiL7004DrSxBNRRplmdQxVQYs17iiC1GjhCSrCcvNuxlF0lSm_Upa7SVGe2ZAa68LXiu4cJwdT4vEjZaTpiVVO9FEx5WnRU9a0S3LfZ7wt8akEn2uTbJGlKpaLxObETdkkHEXPjhbaxdDqQVuURf81vieu9KD_5nuV9gbTsejZHQxuTyEF2bElfZ8gs7q91p91gBtlX6pD-AfIQ48CQ |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7C5lB6SJ9JtyRlCiGnaGNbsuXNbUkbQmnCQrOwORnZI4e2xg7dXcL2kN9eSX6k2wd5XG3GWKOR9In55huAXRmQ8DVJprjOmVBhwIYeJxYTqSyQUgvXi-D0LDqZiE_TcLoGB20tzEr-3vGwrEaF03Y0l7nAPh048cj1yGaUerA-ORuPLpyiXiCYQTNTe8WKJWfSgPUVRtc_v_S_8-hvvPkUnizKK7W8VkXx2xl0_AzG7d_X1JPvg8U8HWQ__xB2fMDwnsNGg0dxVAfQC1jT5UvYG9eC1st9PL-tz5rt4x6Ob6Wul6_g5rSqCFVJ2NCQqhJd13FUK6K8WOVYVNf4-csHpGqmZ_i1xLoEc4l2gzTTa3DoIY7QkcTSChsOfaHJWbCaeIIux15eopPFfQ2T44_nRyes6ejAMiGjOVPKLHmSXFKcx0MZCn-YGgTnhaHyuBYRxb7y_NygUs1DmZOnoszTOs5zX4chCb4JvdK46w2gzHighuSngTRXKJ6qNMoyMicyBSI3qKQPUTuvSdbInduuG0XS8tq-JZ3vE-t7-8L4vg9eZ3hVK37cbRK3gZO0Ba1mC07MbN9tetiZNpinxjL3M37fRmlidgWb6lGlrhazxOXTrZRk3IetOny7wXDuYF_UB7-L5_uO9O0jbLahN_-x0DsGvM3Td82C_QWbW0Th |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mood+and+cognition+after+administration+of+low+LSD+doses+in+healthy+volunteers%3A+A+placebo+controlled+dose-effect+finding+study&rft.jtitle=European+neuropsychopharmacology&rft.au=Hutten%2C+Nadia+R.P.W.&rft.au=Mason%2C+Natasha+L.&rft.au=Dolder%2C+Patrick+C.&rft.au=Theunissen%2C+Eef+L.&rft.date=2020-12-01&rft.pub=Elsevier+B.V&rft.issn=0924-977X&rft.volume=41&rft.spage=81&rft.epage=91&rft_id=info:doi/10.1016%2Fj.euroneuro.2020.10.002&rft.externalDocID=S0924977X20309111 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0924-977X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0924-977X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0924-977X&client=summon |